Chinese Standards Shop Partner of Google-Books Database: 169759 (Nov 10, 2019)
 HOME   Quotation   Tax   Examples Standard-List   Contact-Us   View-Cart
  

YY 0954-2015

Chinese Standard: 'YY 0954-2015'
Standard IDContents [version]USDSTEP2[PDF] delivered inStandard Title (Description)StatusRelated Standard
YY 0954-2015English210 Add to Cart 0--15 minutes. Auto immediate delivery. Nonactive surgical implants - Type I collagen implants - Specific requirements Valid YY 0954-2015
YY 0954-2015Chinese20 Add to Cart <=1-day [PDF from Chinese Authority, or Standard Committee, or Publishing House]

 YY 0954-2015 -- Click to view a PDF In 0~10 minutes time, full copy of this English-PDF will be auto-immediately delivered to your email by our cloud-server.  
Detail Information of YY 0954-2015; YY0954-2015
Description (Translated English): Nonactive surgical implants. Type I collagen implants. Specific requirements
Sector / Industry: Medical Device & Pharmaceutical Industry Standard
Classification of Chinese Standard: C45
Classification of International Standard: 11.040.40
Word Count Estimation: 19,181
Date of Issue: 2015-03-02
Date of Implementation: 2017-01-01
Quoted Standard: GB/T 16886.1; GB/T 16886.3; GB/T 16886.4; GB/T 16886.5; GB/T 16886.6; GB/T 16886.10; GB/T 16886.11; GB/T 16886.12; GB/T 16886.17; GB/T 16886.18; YY/T 0640-2008; YY/T 0771.1; YY/T 0771.2; YY/T 0771.3; YBB 0006; YBB 0007; YBB 0008; YBB 0009; YBB 0010; YBB 0011; ISO 14155-2011
Drafting Organization: Chinese Institute of Food and Drug test
Administrative Organization: National Surgical implants and orthopedic devices Standardization Technical Committee
Regulation (derived from): The State Food and Drug Administration Announcement 2015 No. 8
Proposing organization: China Food and Drug Administration
Issuing agency(ies): China Food and Drug Administration
Summary: This Standard specifies the requirements for injectable collagen implant agent, it is purified (non-crosslinked) I collagen as a raw material preparation. This Standard specifies the implant agent requirements and test methods. Also expected product performance, design attributes, materials, design evaluation, testing methods, clinical evaluation, any post-market monitoring, manufacturing, packaging and information supplied by the manufacturer, and so do the specific instructions. Taking into account the safety of implanted Jing factor. This Standards required by applicable implant agent used clinically in the face of the dermis and/or subcutaneous injection, in order to eliminate or mitigate a variety of causes facial wrinkles and depressions.

YY 0954-2015
YY
MEDICAL INDUSTRY STANDARD
OF THE PEOPLE’S REPUBLIC OF CHINA
ICS 11.040.40
C 45
Nonactive surgical implants - Type I collagen implants
- Specific requirements
无源外科植入物 I型胶原蛋白植入剂
ISSUED ON. MARCH 02, 2015
IMPLEMENTED ON. JANUARY 01, 2017
Issued by. China Food and Drug Administration of China
Table of contents
Foreword ... 3 
1 Scope ... 4 
2 Normative references ... 4 
3 Terms and definitions ... 5 
4 Expected performance ... 7 
5 Design properties ... 7 
6 Material ... 7 
APPENDIX A (Normative) Determination of collagen content ... 17 
APPENDIX B (Normative) Determination of total protein impurity content ... 20 
Appendix C (Normative) Trace element analysis ... 24 
Appendix D (Normative) Determination of melting point ... 26 
Appendix E (Normative) Tryptophan examination ... 27 
Foreword
This standard was drafted in accordance with the rules given in GB/T 1.1-2009.
Some of the contents of this standard may be related to patents. The issuer of
this document is not responsible for identifying such patents.
This standard was proposed by China Food and Drug Administration of China.
This standard shall be under the jurisdiction of the National Technical
Committee for Standardization of Surgical Implants and Orthopedic Devices
(SAC/TC 110).
The drafting organizations of this standard. China Food and Drug Research
Institute.
The main drafters of this standard. Ke Linnan, Fu Bufang, Wang Jian, Tang
Jinglong, Chen Dandan, Feng Xiaoming, Wang Chunren.
Nonactive surgical implants - Type I collagen
implants - Specific requirements
1 Scope
This standard specifies the specific requirements for injectable collagen
implants (abbreviated as implants) which are prepared from purified (non-
cross-linked) type I collagen as a starting material.
This standard specifies the implant technical requirements and testing methods.
It also specifies the expected performance, design properties, materials, design
evaluation, test methods, clinical evaluation, post-marketing surveillance,
manufacturing, packaging, and information provided by the manufacturer,
taking into account the safety factors of implant.
The implants as specified in this standard are suitable for use in dermal layers
and/or subcutaneous injections for clinical use, in order to eliminate or reduce
facial wrinkles and depressions caused by various reasons.
2 Normative references
The following documents are essential to the application of this document. For
the dated documents, only the versions with the dates indicated are applicable
to this document; for the undated documents, only the latest version (including
all the amendments) are applicable to this Standard.
GB/T 16886.1 Biological evaluation of medical devices - Part 1. Evaluation
and testing within a risk management process
GB/T 16886.3 Biological evaluation of medical devices Part 3. Test for
genotoxicity carcinogenicity and reproductive toxicity
GB/T 16886.4 Biological evaluation of medical devices - Part 4. Selection of
tests for interactions with blood
GB/T 16886.5 Biological evaluation of medical devices - Part 5. Test for vitro
cytotoxicity
GB/T 16886.6 Biological evaluation of medical devices - Part 6. Tests for
local effects after implantation
GB/T 16886.10 Biological evaluation of medical devices - Part 10. Tests for
irritation and delayed-type hypersensitivity
GB/T 16886.11 Biological evaluation of medical devices - Part 11. Tests for
systemic toxicity
GB/T 16886.12 Biological evaluation of medical devices - Part 12. Sample
preparation and reference materials
GB/T 16886.17 Biological evaluation of medical devices - Part 17.
Establishment of allowable limits for leachable substances
GB/T 16886.18 Biological evaluation of medical devices - Part 18. Chemical
characterization of materials
YY/T 0640-2008 Non-active surgical implants - General requirements
YY/T 0771.1 Medical devices utilizing animal tissue and their derivatives -
Part 1. Application of risk management
YY/T 0771.2 Medical devices utilizing animal tissue and their derivatives -
Part 2. Controls on sourcing, collection and handling
YY/T 0771.3 Medical devices utilizing animal tissue and their derivatives -
Part 3. Application of risk management
YBB 0006 Borosilicate glass syringes for prefilled syringes
YBB 0007 Chlorinated butyl rubber piston for prefilled syringes
YBB 0008 Bromobutyl rubber piston for prefilled syringes
YBB 0009 Stainless steel injection needle for prefilled syringes
YBB 0010 Polyisoprene rubber needle guard for prefilled syringes
YBB 0011 Prefilled syringe assembly (with injection needle)
Pharmacopoeia of the People's Republic of China (2010 version)
ISO 14155 (All Parts) Clinical investigation of medical devices for human
subjects
3 Terms and definitions
The following terms and definitions apply to this document.
b) Regardless of the use of collagen implants for cosmetic and/or tissue and
organ reconstruction in order to make the users satisfy with the aesthetic
or psychological effects, it shall consider the risks or side effects of the
impurities in the process of use; AND it shall minimize such risks.
7.2 Preclinical evaluation
7.2.1 General preclinical for preclinical evaluation
The preclinical evaluation of collagen implants shall comply with the
requirements in 7.2 of YY/T 0640-2008.
In accordance with the requirements of the experiment, all test samples shall
be the finally sterilized equipment or components.
The number of samples shall be chosen in accordance with the requirements
of this standard.
Note. The preclinical evaluation and the proven test methods in this standard
reflect the current level of technological development.
7.2.2 Appearance
It shall be white, milky white or yellowish viscous liquid, without visible foreign
matter.
7.2.3 Loading capacity
It shall not be less than 90% of the indicated capacity.
7.2.4 Dynamic viscosity
It shall be within the indicated range.
7.3 Chemical characteristics
7.3.1 Type I collagen identification
After the SDS-polyacrylamide gel electrophoresis analysis, COMPARE the
electrophoretic bands of the samples and the type I collagen reference product,
AND the electrophoretic bands shall be consistent.
7.3.2 Collagen content
It shall be 80% ~ 120% of the indicated amount.
7.3.3 Protein impurity analysis
the test results shall comply with the provisions of 7.2.4.
8.4 Identification of type I collagen
USE the 3% acetic acid or 0.01 mol/L hydrochloric acid to dilute the sample into
a solution with a collagen concentration of 1 mg/mL ~ 2 mg/mL. FOLLOW the
methods as specified in Appendix IV C of the Pharmacopoeia of the People's
Republic of China (volume III) (2010 version); USE the SDS-polyacrylamide gel
electrophoresis, with the separation gel concentration in 7% AND the sample
amount of 20 µL. Through analyzing the sample and type I collagen reference
substance, the results shall comply with the provisions of 7.3.1.
8.5 Collagen content
FOLLOW the method of Appendix A, AND the results shall comply with the
provisions of 7.3.2.
8.6 Protein impurity analysis
FOLLOW the method of Appendix B, AND the results shall comply with the
provisions of 7.3.3.
8.7 pH
FOLLOW the methods as specified in Appendix VI H of Pharmacopoeia of the
People's Republic of China (volume II) (2010 version), AND the results shall
comply with the provisions of 7.3.4.
8.8 Residues on ignition
FOLLOW the methods as specified in Appendix VI N of the Pharmacopoeia of
the People's Republic of China (volume II) (2010 version), AND the results shall
comply with the provisions of 7.3.5.
8.9 Total heavy metals and trace elements
8.9.1 Total amount of heavy metals (calculated as Pb)
The residues left under the residues on ignition shall follow the 2nd method of
Appendix VIII H of the Pharmacopoeia of the People's Republic of China
(volume II) (2010 version), AND the results shall comply with the provisions of
7.3.6.1.
8.9.2 Trace elements
FOLLOW the methods as specified in Appendix C; AND the results shall comply
with the provisions of 7.3.6.2.
The requirements of Chapter 8 in YY/T 0......
Related standard:   YY 0948-2015  YY/T 0962-2014
   
 
Privacy   ···   Product Quality   ···   About Us   ···   Refund Policy   ···   Fair Trading   ···   Quick Response
Field Test Asia Limited | Taxed in Singapore: 201302277C | Copyright 2012-2019